Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$206.0K
5.02K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 5.02K shares of NEKTAR THERAPEUTICS valued at approximately $206.0K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 1/20/2026ACC: 0001959173-26-000377
Officer· Chief R&D Officer
Since Oct 2019
5.02K
Shares to sell
$206.0K
Approx. market value
3.87K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months3
Restricted Stock Vesting
Compensation
12/13/2024
3.34KRestricted Stock Vesting
Compensation
11/15/2024
525.00Restricted Stock Vesting
Compensation
8/15/2024
1.00Total acquired3.87K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
12/13/2024 | Restricted Stock Vesting Compensation | 3.34K | — |
11/15/2024 | Restricted Stock Vesting Compensation | 525.00 | — |
8/15/2024 | Restricted Stock Vesting Compensation | 1.00 | — |
| Total | 3.87K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
1.16K
Market value
$68.1K
11/25/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
3.87K
Market value
$137.9K
1/20/2026
Total
Units
5.02K
Value
$206.0K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
11/25/2025 | 1.16K | $68.1K | — | Completed |
| Planned — Approximate Date | ||||
1/20/2026 | 3.87K | $137.9K | NASDAQ | Planned |
| Total | 5.02K | $206.0K | ||